Interpreting the association between cannabis use and increased risk for schizophrenia

Dialogues in Clinical Neuroscience

Volumn 7, Issue 1, 2005, Pages 81-85

  Weiser, Mark ^b   Noy, Shlomo ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Cannabinoid receptor; Cannabis; Endogenous cannabinoids; Risk factor; Schizophrenia

Indexed keywords

CANNABINOID RECEPTOR; CANNABIS;

BRAIN REGION; CANNABIS ADDICTION; CEREBROSPINAL FLUID EXAMINATION; CINGULATE GYRUS; DISEASE ASSOCIATION; HUMAN; LONGITUDINAL STUDY; NETHERLANDS; NEW ZEALAND; PATHOGENESIS; PREFRONTAL CORTEX; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SWEDEN;

HUMANS; MARIJUANA ABUSE; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 17444413053     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Degenhardt L, Hall W. The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. Psychol Med. 2001;31:659-668.
2. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol use and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry. 1997;54:313-321.
3. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders' with alcohol and other drug use. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511-2518.
4. Cantwell R, Brewin J, Glazebrook C, et al. Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry. 1999;174:150-153.
5. Hambrecht M, Hafner H. Substance use and the onset of schizophrenia. Biol Psychiatry. 1996;40:1155-1163.
6. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987;2:1483-1486.
7. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self-reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325:1199.
8. Van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156:319-327.
9. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325:1212-1213.
10. Weiser M, Reichenberg A, Rabinowitz J, et al. Self-reported drug use in male adolescents with behavioral disturbances, and follow-up for future schizophrenia. Biol Psychiatry. 2003;54:655-660.
11. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.
12. Sobue T, Yamamoto S, Hara M, Sasazuki S, Sasaki S, Tsugane S. Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women: the JPHC study. Int J Cancer. 2002;99:245-251.
13. Sullivan LM, Massaro JM, D'Agostino RB, Sr. Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med. 2004;23:1631-1660.
14. Results from the 2003 National Survey on Drug Use and Health: National Findings. Series H-25, DHHS Publication No. SMA 04-3964. Rockville, Md: Office of Applied Studies, NSDUH; 2004.
15. Boydell J, Van Os J, Lambri M, et al. Incidence of schizophrenia in southeast London between 1965 and 1997. Br J Psychiatry. 2003;182:45-49.
16. Cavanagh JT, Shajahan PM. Increasing rates of hospital admission for men with major mental illnesses: data from Scottish mental health units, 1980-1995. Acta Psychiatr Scand. 1999;99:353-359.
17. Woogh C. Is schizophrenia on the decline in Canada? Can J Psychiatry. 2001;46:61-67.
18. Kendell RE, Malcolm DE, Adams W. The problem of detecting changes in the incidence of schizophrenia. Br J Psychiatry. 1993;162:212-218.
19. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry. 2004;184:110-117.
20. Tien AY, Eaton WW. Psychopathologic precursors and sociodemographic risk factors for the schizophrenia syndrome. Arch Gen Psychiatry. 1992;49:37-46.
21. Carter JW, Parnas J, Cannon TD, Schulsinger F, Mednick SA. MMPI variables predictive of schizophrenia in the Copenhagen High-Risk Project: a 25-year follow-up. Acta Psychiatr Scand. 1999;99:432-440.
22. Van Os J, Jones PB. Neuroticism as a risk factor for schizophrenia. Psychol Med. 2001;31:1129-1134.
23. Swadi H, Bobier C. Substance, use disorder comorbidity among inpatient youths with psychiatric disorder. Aust N Z J Psychiatry. 2003;37:294-298.
24. Agosti V, Nunes E, Levin F. Rates of psychiatric comorbidity among US residents with lifetime cannabis dependence. Am J Drug Alcohol Use. 2002;28:643-652.
25. Rey JM, Sawyer MG, Raphael B, Patton GC, Lynskey M. Mental health Of teenagers who use cannabis. Results of an Australian survey. Br J Psychiatry. 2002;180:216-221.
26. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance use comorbidity in schizophrenia. Biol Psychiatry. 2001;50:71-83.
27. Rodriguez De Fonseca F, Gorriti MA, Bilbao A, et al. Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia. Neurotox Res. 2001;3:23-35.
28. Weinberger DR, Aloia MS, Goldberg TE, Berman KF. The frontal lobes and schizophrenia. J Neuropsychiatry Clin Neurosci. 1994;6:419-427.
29. Andreasen NC. A unitary model of schizophrenia: Bleuler's "fragmented phrene" as schizencephaly. Arch Gen Psychiatry. 1999;56:781-787.
30. Wenger T, Moldrich G, Furst S. Neuromorphological background of cannabis addiction. Brain Res Bull. 2003;61:125-128.
31. Lieberman JA, Kinon BJ, Loebel AD. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull. 1990;16:97-110.
32. Iversen L. Cannabis and the brain. Brain. 2003;126:1252-1270.
33. 1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:355-360.
34. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience. 2001;103:9-15.
35. Ujike H, Takaki M, Nakata K, et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry. 2002;7:515-518.
36. 1): association study using a single-base polymorphism in coding exon 1. Am J Med Genet. 2001;105:749-752.
37. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2003;2:5.
38. Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004;29:2108-2114.
39. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999;10:1665-1669.